Marquette Asset Management’s Adicet Bio ACET Stock Holding History

Marquette Asset Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,759	Closed	-$38.6K	–	193
2023 Q3	$38.6K	Buy	+1,759	New	+$62.1K	0.01%	146

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marquette Asset Management's ACET Position: Q4 2023 in Review

Marquette Asset Management sold out of Adicet Bio (ACET) in Q4 2023, closing a stake of 1,759 shares — an estimated $38.6K sold.

Marquette Asset Management first reported a position in ACET in Q3 2023 and held it in 1 quarter. The position peaked at $38.6K in Q3 2023. 76 funds tracked by Wall St. Rank hold ACET as of Q4 2023.

Marquette Asset Management reported no remaining Adicet Bio position as of Q4 2023 after selling out during the quarter.
Marquette Asset Management sold 1,759 Adicet Bio shares in Q4 2023, an estimated $38.6K.
Marquette Asset Management first reported a position in Adicet Bio in Q3 2023 and held it in 1 quarter.
Marquette Asset Management's Adicet Bio position peaked at $38.6K in Q3 2023.
76 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2023.

Based on Marquette Asset Management's 13F filing for Q4 2023, filed 2 Feb 2024.